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Abstract Excess visceral adipose tissue (VAT) is asso-
ciated with a cluster of metabolic abnormalities. A new
dual-energy X-ray absorptiometry (DXA)-based VAT
measurement approach, CoreScanTM, computes VAT mass
and volume within the android region of a total body DXA
scan. However, there have been no reference values
developed for this method. The objective of this study was
to determine the normal reference ranges for DXA-derived
VAT in young, healthy, premenopausal women. We also
sought associations between VAT, blood lipids, glucose,
insulin and insulin resistance. In 120 randomly selected,
normal weight, Caucasian women aged 20–40 years, we
measured body fat (BF), VAT and lean mass by DXA. We
also assessed blood pressure, waist and hip circumference,
waist-to-hip ratio, body mass index, fasting glucose, insu-
lin, triglycerides (TG), and high- (HDL) and low-density
lipoproteins. Insulin resistance was evaluated by the
homeostasis model assessment (HOMA). VAT mass
accounted for 0.37 ± 0.3 % of weight and 1.11 ± 0.72 %
of BF. Mean VAT mass and volume were 235.9 ± 183 g
(95 % CI 202.7–269.1) and 250.3 ± 194.5 cm3 (95 % CI
215.1–285.4), respectively. Anthropometric indices mod-
erately correlated with VAT. VAT significantly correlated
with HDL (R = -0.193; P = 0.03), glucose (R = 0.252;
P = 0.005) and HOMA (R = 0.184; P = 0.049). In this
study, we provide normal values of VAT mass and volume
measured by DXA and determined for healthy, normal
weight, Caucasian women aged 20–40 years. Even in such
strictly selected population VAT correlated positively with
insulin resistance and inversely with HDL.
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Introduction
Visceral adipose tissue (VAT) accumulates primarily deep
in the peritoneal cavity within the upper part of the abdo-
men and infiltrates the liver, stomach, pancreas and the
mesentery. In contrast to abdominal subcutaneous adipose
tissue (SAT), VAT is highly vascularized and contains
large fat cells, which easily disrupt secreting proinflam-
matory cytokines, adipokines and hormones to the blood
[1, 2]. It is also associated with impaired non-esterified
fatty acid (NEFA) metabolism, leading to a hyperlipolytic
state in which adipose cells are resistant to the antilipolytic
effects of insulin. The resulting NEFA flux to the liver may
induce increased hepatic production of glucose. Excess
VAT is associated with a risk of type 2 diabetes, dyslipi-
demia, hypertension, cardiovascular diseases and cancer
[3–5].
VAT may be assessed by surrogate methods, such as
waist circumference (WC), waist-to-hip ratio (WHR),
sagittal abdominal diameter and index of central obesity. It
can be indirectly measured by a 3D full body scanner as
body volume index or through bioelectric impedance ana-
lysis or dual-energy X-ray absorptiometry (DXA). Until
recently, computed tomography (CT) and magnetic reso-
nance imaging (MRI) have been the only widely used
techniques for direct measurement of VAT mass and vol-
ume. However, these techniques are costly, time-consum-
ing or associated with a risk of radiation. Earlier studies
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demonstrated the potential usefulness of DXA-derived
indices to supply accurate measurements of VAT in addi-
tion to body composition [6, 7]. Recently, a new DXA-
based VAT measurement approach, CoreScan, has been
developed. The CoreScan algorithm computes VAT mass
and volume within the android region of a total body DXA
scan by subtracting SAT from total android fat. VAT
computed by DXA has been validated using CT across a
broad population of adults between 18 and 90 years of age
and a wide range of BMI [8]. However, regardless of the
method used for the assessment, there have been no ref-
erence values determined for VAT in healthy individuals
and specific for gender, race and age. Therefore, in this
study, we measured body composition in a homogenous
group of young, healthy, premenopausal Caucasian women
to determine the normal reference ranges for DXA-derived
VAT. We also sought associations between VAT, blood




Using local electoral lists, we randomly invited healthy
women aged 20–40 years to participate in the study. The
inclusion criteria included: BMI between 18.6 and 25.0 kg/
m2, regular menstruation, no alcohol abuse and no medical
conditions that required pharmacological treatment. We
excluded women with a history of malignancy and prior
hypertension, dyslipidemia, abnormal glucose tolerance
(including gestational diabetes) and rapid weight changes
(more than 3 kg) within the last 12 months. All subjects
underwent a routine physical examination with a mea-
surement of blood pressure in a supine position. Overall, of
247 women who participated in the study, we included 120
women who met the entry criteria.
This study complied fully with all applicable institu-
tional and governmental regulations concerning the ethical
use of human volunteers and with the terms of the Decla-
ration of Helsinki. The Pomeranian Medical University
Ethics Committee approved the study protocol, and all the
recruited subjects gave their written informed consent.
Anthropometric measurements
Height, WC and hip circumference were measured to the
nearest 0.5 cm. WC was determined at the midpoint
between the bottom of the rib cage and the iliac crest. Hip
circumference was measured as the maximal circumfer-
ence over the buttocks. From weight, height, WC and hip
circumference, BMI and WHR were calculated. BMI was
calculated as weight (kg) divided by height (m) squared.
WHR was calculated as WC (cm) divided by hip circum-
ference (cm) [9].
Biochemical analyses
Biochemical analyses included fasting glucose, insulin and
blood lipid levels. Serum glucose was measured after
overnight fasting by the glucose oxidase method (Glucose
Konelab/T Series, Fisher Scientific, Poland). Insulin was
measured by the immunoenzymatic method (DPC Bier-
mann GmbH, Bad Neuheim, Germany). From fasting
glucose and insulin measurements, a HOMA-IR (homeo-
stasis model assessment–insulin resistance) index was
calculated. Serum total cholesterol, high-density lipopro-
tein cholesterol (HDL), low-density lipoprotein cholesterol
(LDL) and TG were determined by enzymatic colorimetric
methods using Roche Diagnostics assays.
Measurements of visceral, android, gynoid and total fat
Body composition, including total body fat (BF), regional
fat (android, gynoid and visceral) and lean mass, was
measured by DXA (GE Lunar Prodigy; Madison, WI,
USA; 14.1 enCore software version with CoreScanTM)
using automatic total body scan mode. The regions of
interest (ROI) for regional body composition were defined
using the software provided by the manufacturer. The
android region (Android), located over the abdomen, is
roughly 10 cm in height, extending from the iliac crest
toward the head for 20 % of the distance from the iliac
crest to the base of the skull. The software algorithm works
through detection of the width of the SAT layer on the
lateral part of the abdomen and the anterior–posterior
thickness of the abdomen, which can be determined using
X-ray attenuation (Fig. 1). In the android ROI, we calcu-
lated SAT by subtracting VAT from android fat mass. The
hip ROI (Gynoid) was defined superiorly below the pelvis
cut line as 1.5 times the height of the android ROI, infe-
riorly below the superior line by two times the height of the
Android ROI and laterally at the outer leg cut lines.
Statistical analysis
Data are presented as mean ± standard deviation (95 %
CI). Differences among the age bands (20–30 and
30–40 years) in normally and non-normally distributed
variables were evaluated by Mann–Whitney U test or
paired Student’s t test as appropriate. Because % BF, SAT,
waist and hip circumference, WHR and Gynoid showed
markedly skewed distributions, logarithmic transforma-
tions of these measurements were performed. Linear
Spearman’s rank correlation coefficients were used to
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determine the relationship between body composition,
anthropometric measurements and metabolic parameters.
We used the 5 % significance for all tests.
Results
Baseline characteristics are given in Table 1. Mean VAT/
SAT ratio in the android ROI was 0.23 ± 0.14 %. VAT
mass accounted for only 0.37 % of weight and 1.1 % of
BF. Mean values of anthropometric measurements, blood
pressure, serum glucose and insulin, and blood lipids were
normal. When we analyzed the data in two age bands (data
not shown), below (n = 40) and above 30 years of age
(n = 80), we found no statistical differences in body
composition, including VAT, except for a slightly higher
VAT/SAT ratio in the older age band (0.18 ± 0.11 and
0.25 ± 0.15, respectively; P = 0.011).
VAT was highly correlated with android fat (R = 0.832;
P \ 0.0001). Other correlations between body composition,
anthropometric measurements and metabolic parameters are
shown in Table 2. Anthropometric indices (WC, hip cir-
cumference, WHR and BMI) moderately correlated with
VAT. Of these indices, BMI and WC were the most accurate
measures of adiposity and regional fat depots. SAT, Android
and BF showed weak but significant correlations with TG and
HDL. Interestingly, VAT was also inversely associated with
HDL level, but was the only measure that correlated with
fasting glucose and HOMA. HDL (but not other metabolic
parameters) inversely correlated with BMI (R = -0.208;
P = 0.017) and WC (R = -0.226; P = 0.009). None of the
studied parameters was associated with blood pressure values.
Discussion
In this study, for the first time, we have presented mean
values and ranges of VAT assessed by DXA, determined in
healthy, premenopausal Caucasian women. These data may
serve as reference values for future research performed on
similar populations. Increasing evidence suggests that VAT
is an important measurement to make in assessing different
phenotypes of obesity because its ectopic accumulation,
particularly in the liver, is strongly associated with risk of
metabolic diseases [5, 10]. However, until recently, routine
use of this measurement has been limited by cost and access
to CT or MRI, which have been the research tools for mea-
suring VAT.
Previous research demonstrated the potential usefulness
of DXA to supply accurate measurements of VAT. In 2000,
Bertin et al. [7] compared DXA and anthropometric data
and their combinations to the VAT area calculated from a
CT scan. They found that the transverse internal diameter
at umbilical level, which corresponded to the lean core of
abdomen stripped of SAT, was the best predictor of VAT.
Based on these findings, they developed an empiric
Fig. 1 The assessment of visceral and SAT in the android region of interest by dual-energy X-ray absorptiometry. Total body scan of the study
subject
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equation to calculate VAT from height, sagittal diameter,
and DXA-derived indices. Basically, the CoreScan algo-
rithm is based on the similar assumption. It works through
detection of two key parameters: (i) the width of the SAT
layer on the lateral aspects of the abdomen and (ii) the
anterior–posterior thickness of the abdomen, which can be
attained using the DXA tissue attenuation image. A simple
geometric model using these measures is used to estimate
the android SAT. Therefore, the CoreScan application
computes VAT by subtracting the android SAT from the
total android fat. This new DXA software application
provides a high degree of precision and accuracy in a single
measurement [8–11]. Moreover, DXA is fast, safe and
presents little discomfort or inconvenience to the subjects.
DXA exposes subjects to a much lower radiation dose than
CT (below 1.00 lSv for a standard-mode total body DXA
exam vs. 3,100 lSV of radiation for an abdominal CT
scan), making it suitable for repeated measurements.
Finally, MRI or CT measurements predict cardiovascular
risk in relation to VAT area or volume, while DXA addi-
tionally offers an assessment of VAT mass. The greatest
utility for CoreScan would be to characterize cardiometa-
bolic risk, not only as a fast screening tool in subjects at
risk but also as a tool for assessment of therapeutic effi-
cacy, as longitudinal assessment of body composition
during controlled under- and overfeeding shows that small
decreases and increases in fat mass are associated with
corresponding decreases and increases in insulin secretion
and insulin sensitivity [12]. Moreover, recent data suggest
that visceral fat increases and decreases proportionately
with short-term weight gain and loss [13].
Table 1 Baseline characteristics of study participants
Mean SD (95 % CI)
Age (years) 32.08 5.05 (31.2–33.0)
Weight (kg) 61.14 6.98 (59.9–62.4)
Height (cm) 166.55 5.69 (164.2–166.7)
Body mass index (kg/cm2) 22.23 1.82 (21.9–22.6)
WC (cm) 75.57 6.96 (74.3–76.8)
Hip circumference (cm) 95.72 5.94 (94.6–96.8)
Waist/hip ratio 0.79 0.05 (0.78–0.80)
Lean tissue (kg) 39.31 5.14 (38.4–40.2)
BF (kg) 19.70 4.32 (18.9–20.5)
BF (%) 31.75 4.69 (30.9–32.6)
Android fat (g) 1214.3 476.9 (1128.4–1300.2)
Gynoid fat (g) 3787.0 815.2 (3639.7–3934.3)
VAT (g) 235.93 183.4 (202.7–269.1)
VAT (cm3) 250.25 194.5 (215.1–285.4)
SAT (g) 978.38 336.1 (917.6–1039.1)
Visceral/SAT 0.23 0.14 (0.20–0.26)
VAT/BF (%) 1.11 0.72 (0.98–1.24)
VAT/Weight (%) 0.37 0.27 (0.32–0.42)
Glucose (mmol/L) 5.0 0.39 (4.94–5.1)
Insulin (lIU/mL) 6.65 3.3 (6.05–7.25)
HOMA 1.49 0.79 (1.35–1.63)
Total cholesterol (mmol/L) 4.82 0.93 (4.66–4.99)
Cholesterol HDL (mmol/L) 1.68 0.38 (1.61–1.75)
Cholesterol LDL (mmol/L) 2.74 0.82 (2.6–2.91)
TG (mmol/L) 0.83 0.47 (0.75–0.92)
Systolic blood pressure (mmHg) 116.7 14.01 (114.1–119.2)
Diastolic blood pressure (mmHg) 76.57 8.1 (74.7–78.3)
Table 2 Correlations between body composition, anthropometric measurements and metabolic parameters
VAT (g) VAT (cm3) SAT (g) Android (g) Gynoid (g) BF (g) Waist (cm) BMI (kg/m2)
Anthropometric measurements
Waist (cm) 0.645 0.642 0.703 0.752 0.571 0.722 0.717
Hip (cm) 0.336 0.338 0.535 0.522 0.683 0.613 0.598 0.571
Waist/hip ratio 0.535 0.531 0.398 0.477 0.119 0.365 0.713 0.400
BMI (kg/m2) 0.686 0.683 0.760 0.796 0.720 0.826 0.717
Metabolic parameters
HDL (mmol/L) 20.193 -0.194 -0.198 -0.222 -0.076 -0.182 -0.226 -0.208
LDL (mmol/L) 0.050 0.049 0.117 0.097 0.102 0.094 -0.075 -0.035
TG (mmol/L) 0.176 0.177 0.251 0.254 0.133 0.214 0.151 0.106
Insulin (lIU/mL) 0.138 0.140 0.075 0.097 0.107 0.120 0.006 0.023
Glucose (mmol/L) 0.252 0.250 0.018 0.096 0.002 0.076 0.014 0.029
HOMA 0.184 0.179 0.074 0.111 0.099 0.128 0.062 0.009
Systolic blood pressure (mmHg) 0.088 0.090 0.036 0.059 0.327 0.065 0.144 0.007
Diastolic blood pressure (mmHg) 0.122 0.120 0.079 0.101 0.022 0.097 0.171 0.051
Numbers in each cell describe Spearman’s rank correlation coefficient. Significant correlations are given in bold
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Numerous clinical studies have documented significant
associations between CT-derived VAT and metabolic dis-
eases [14–18]. To our knowledge, only one clinical study has
evaluated VAT by DXA in a healthy population. In a cross-
sectional analysis of body composition across a wide range of
age bands (25 subjects per each band) in healthy Italian blood
donors, Bazzocchi et al. [19] demonstrated that VAT mass
assessed by DXA was age- and gender-dependent; the mean
VAT value in their study was 149 ± 156 g in females aged
18–30 years and 358 ± 326 g in those aged 31–40 years.
Overall, their results regarding VAT are similar to ours,
although there are differences between BMI, lean mass and
SAT results in the two studies. This strongly suggests that
future research is needed to determine cutoff values for DXA-
derived VAT to identify subjects at risk for metabolic syn-
drome, as has been determined for VAT measured by CT
[17]. Recently, in a large cohort of Polish women represent-
ing a wide range of BMI, we found that Android mass above a
threshold value of 1,500 g increased the risk of metabolic
syndrome by 2.07 times (95 % CI 1.05–4.09) [20]. Since in
the present study Android constituted *20 % of VAT, we
can speculate that the VAT cutoff value for metabolic syn-
drome determined in healthy women of normal weight aged
between 20 and 40 years would be about 300 g.
We also found that VAT was positively correlated with
fasting glucose level and HOMA and negatively with HDL.
These results suggest that even in healthy and lean indi-
viduals, excess VAT may be associated with a cluster of
metabolic abnormalities, including insulin resistance,
abnormal lipid profile and ectopic (e. g. epicardial) fat
deposition [21, 22], which appear to be key factors in the
pathogenesis of metabolic syndrome and metabolically
obese but normal-weight phenotype. This underlines the
importance of developing accurate methods for early
quantification of VAT. Our results indicate that among the
surrogate methods of measurement of total/abdominal
obesity, WC and BMI better assess VAT than WHR or hip
circumference. However, anthropometric variables were
only moderately associated with VAT (R \ 0.7), similarly
as in earlier studies in which VAT was measured by CT
[7]. Moreover, WC and BMI, in contrast to VAT, corre-
lated only with HDL but not with other metabolic
parameters.
When interpreting our data, it is appropriate to consider
certain limitations of our study. The main limitation is its
cross-sectional design. Hence, the associations presented
between independent factors and outcome variables do not
necessarily represent causal relationships. We presented
data from a relatively large sample of healthy, premeno-
pausal Polish women with narrow BMI, BF and age ranges.
Therefore, data presented in this study might not be
applicable for general populations or other ethnicities. A
study that involves a broader range of age and BMI is
important for further validation of these findings. Second,
in addition to possible inter-operator variation, there is
intra-equipment variation in DXA measurements, even
within equipment supplied by the same manufacturer,
which may influence the reliability of measurements in
population-based studies. Moreover, in some cases, an
automatic scan mode does not fix the markers accurately
within the studied ROI, which requires manual corrections.
To minimize such technical errors, during the entire study
period, we used the same DXA scanner and software ver-
sion. Additionally, all scans were analyzed by the same
technician.
In conclusion, in this study, we provide normal values of
VAT mass and volume measured by DXA and determined
for healthy, normal weight, Caucasian women aged
between 20 and 40 years. Even in such strictly selected
population, VAT appears to predict the risk of insulin
resistance and unfavorable lipid profile.
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